The Institute for Research in Immunology and Cancer – Commercialization of Research (IRICoR) of Université de Montréal will attend the 11th Annual International Partnering Conference BIO-EUROPE Spring. This conference is being held from March 20 to March 22, 2017 at the CCIB Convention Center in Barcelona, Spain.
For more information about BIO-EUROPE Spring 2017 click here : BIO-EUROPE Spring 2017
For a meeting with the IRICoR representatives during the conference, please contact Steven Klein ( firstname.lastname@example.org).
About the Institute for Research in Immunology and Cancer – Commercialization of Research
As Université de Montréal’s drug discovery and project maturation cluster, IRICoR is a not-for-profit organization based at IRIC, with the mandate to accelerate the discovery, development and commercialization of novel therapies in cancer, immunotherapy and related fields. Since its creation in 2008, IRICoR successfully invests in and supports cutting-edge projects with disruptive technologies to rapidly translate innovation into patient-accessible therapies, through either co-development partnerships with industry or company creation. IRICoR seamlessly integrates business-related expertise with industry-level drug discovery in a world-renowned research institute, providing academics with access to a full drug discovery chain with one of the largest academia-based medicinal chemistry groups in Canada. For more information about IRICoR: www.iricor.ca
Steven Klein Ph.D., MBA
Vice-President, Business Development
T +1 514 343.6647